Relative to [[ziconotide]], leconotide is advantageous in that it is significantly less [[toxic]], and for that reason can be administered [[intravenous injection|intravenous]]ly as opposed to via [[intrathecal injection]].<ref>{{cite book|title=Nervous System Diseases: Advances in Research and Treatment: 2011 Edition|url=https://books.google.com/books?id=RQTtLhbqJE4C&pg=PA217|date=9 January 2012|publisher=ScholarlyEditions|isbn=978-1-4649-2221-3|pages=217–}}</ref><ref name="KolosovGoodchild2010">{{cite journal|last1=Kolosov|first1=Anton|last2=Goodchild|first2=Colin S.|last3=Cooke|first3=Ian|title=CNSB004 (Leconotide) Causes Antihyperalgesia Without Side Effects When Given Intravenously: A Comparison with Ziconotide in a Rat Model of Diabetic Neuropathic Pain|journal=Pain Medicine|volume=11|issue=2|year=2010|pages=262–273|issn=1526-2375|doi=10.1111/j.1526-4637.2009.00741.x}}</ref><ref name="KolosovAurini2011">{{cite journal|last1=Kolosov|first1=Anton|last2=Aurini|first2=Lucia|last3=Williams|first3=Elizabeth D.|last4=Cooke|first4=Ian|last5=Goodchild|first5=Colin S.|title=Intravenous Injection of Leconotide, an Omega Conotoxin: Synergistic Antihyperalgesic Effects with Morphine in a Rat Model of Bone Cancer Pain|journal=Pain Medicine|volume=12|issue=6|year=2011|pages=923–941|issn=1526-2375|doi=10.1111/j.1526-4637.2011.01118.x}}</ref>
